- Home
- GANX vs PMVP Comparison
GANX vs PMVP Comparison
Compare GANX & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- PMVP
- Stock Information
- Founded
- GANX 2017
- PMVP 2013
- Country
- GANX United States
- PMVP United States
- Employees
- GANX N/A
- PMVP N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- GANX Health Care
- PMVP Health Care
- Exchange
- GANX Nasdaq
- PMVP Nasdaq
- Market Cap
- GANX 69.0M
- PMVP 77.4M
- IPO Year
- GANX 2021
- PMVP 2020
- Fundamental
- Price
- GANX $1.58
- PMVP $1.25
- Analyst Decision
- GANX Strong Buy
- PMVP Strong Buy
- Analyst Count
- GANX 5
- PMVP 1
- Target Price
- GANX $8.20
- PMVP $5.00
- AVG Volume (30 Days)
- GANX 526.2K
- PMVP 2.7M
- Earning Date
- GANX 11-13-2025
- PMVP 11-06-2025
- Dividend Yield
- GANX N/A
- PMVP N/A
- EPS Growth
- GANX N/A
- PMVP N/A
- EPS
- GANX N/A
- PMVP N/A
- Revenue
- GANX N/A
- PMVP N/A
- Revenue This Year
- GANX N/A
- PMVP N/A
- Revenue Next Year
- GANX N/A
- PMVP N/A
- P/E Ratio
- GANX N/A
- PMVP N/A
- Revenue Growth
- GANX N/A
- PMVP N/A
- 52 Week Low
- GANX $1.36
- PMVP $0.81
- 52 Week High
- GANX $3.19
- PMVP $1.84
- Technical
- Relative Strength Index (RSI)
- GANX 39.85
- PMVP 43.37
- Support Level
- GANX $1.55
- PMVP $1.12
- Resistance Level
- GANX $1.78
- PMVP $1.40
- Average True Range (ATR)
- GANX 0.13
- PMVP 0.16
- MACD
- GANX -0.03
- PMVP -0.03
- Stochastic Oscillator
- GANX 6.00
- PMVP 17.94
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.